Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort

(2016) Christopher W Teshima et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study

(2015) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

(2015) Filip Baert et al.   GUT

Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD

(2015) Konstantinos Papamichael et al.   INFLAMMATORY BOWEL DISEASES

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

(2014) C. Ma et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

(2014) Y. Mazor et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases

(2014) B. Pariente et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Endoscopic and Medical Management of Fibrostenotic Crohn's Disease

(2014) Clara Thienpont et al.   DIGESTIVE DISEASES

Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study

(2014) Ana Echarri et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics

(2014) A Jauregui-Amezaga et al.   GUT

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Predictors of response to Infliximab in children with luminal Crohn's disease

(2014) Zubin Grover et al.   Journal of Crohns & Colitis

P566 A matrix-based prediction model for primary response to infliximab in Crohn's disease patients

(2014) T. Billiet et al.   Journal of Crohns & Colitis

P136 Simple endoscopic score for Crohn's disease (SES-CD) predicts long-term prognosis in Crohn's disease patients with clinical remission

(2014) M. Naganuma et al.   Journal of Crohns & Colitis

Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative

(2014) R.V. Bryant et al.   Journal of Crohns & Colitis

Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort

(2013) J. D. Ryan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Metabolic Profiling Predicts Response to Anti-Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis

(2013) Sabrina R. Kapoor et al.   ARTHRITIS AND RHEUMATISM

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment

(2013) Gordon W. Moran et al.   Clinical Gastroenterology and Hepatology

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease

(2013) Ingrid Ordás et al.   GASTROENTEROLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

(2013) Jason W. Harper et al.   INFLAMMATORY BOWEL DISEASES

Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease

(2013) Sorcha O’Meara et al.   INFLAMMATORY BOWEL DISEASES

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

(2013) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease

(2012) P. S. A. Silva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

(2012) F. Zorzi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of a new Immunoassay for the accurate determination of anti-infliximab antibodies in Crohnʼs Disease

(2012) Hirotsugu Imaeda et al.   INFLAMMATORY BOWEL DISEASES

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

(2012) Pauliina Molander et al.   INFLAMMATORY BOWEL DISEASES

Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease

(2012) Rebecca L Roberts et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice

(2012) Roy Nattiv   WORLD JOURNAL OF GASTROENTEROLOGY

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

(2011) D. Laharie et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center

(2011) Russell D. Cohen et al.   INFLAMMATORY BOWEL DISEASES

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review

(2011) Lani Prideaux et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

(2011) Edward V. Loftus et al.   Journal of Crohns & Colitis

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Fecal calprotectin is a predictive marker of relapse in Crohnʼs disease involving the colon: a prospective study

(2010) Lamia Kallel et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients

(2010) Evelien Bultman et al.   GASTROENTEROLOGY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

Endoscopic monitoring of infliximab therapy in Crohnʼs disease

(2010) Clas-Göran af Björkesten et al.   INFLAMMATORY BOWEL DISEASES

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies

(2009) M. ALLEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease

(2009) Franca Viola et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

W1102 Anti-TNF Therapy for Crohn's Disease: Predictors of Dose Escalation and Early Discontinuation By 1 Year of Therapy

(2009) Amar S. Naik et al.   GASTROENTEROLOGY

T1215 Subanalysis of Remission Rates By Duration of Disease in Adalimumab-Treated Patients with Crohn's Disease: the Care Trial

(2009) Walter Reinisch et al.   GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

(2009) Charlotte Magdelaine-Beuzelin et al.   Pharmacogenetics and Genomics

Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease

(2009) Corey A. Siegel et al.   Therapeutic Advances in Gastroenterology

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab treatment for symptomatic Crohn’s disease strictures

(2008) A.-L. PELLETIER et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

(2008) Lucien Aarden et al.   CURRENT OPINION IN IMMUNOLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET

Pharmacogenetics of Crohn’s disease

(2008) Helga-Paula Török et al.   PHARMACOGENOMICS

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY